Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
  • inderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Följda bolag
    • Teamet
Pressmeddelande

Lifecare strengthens miniaturisation roadmap with new patent applications

Lifecare

Bergen, Norway, 24 September 2025 – Lifecare ASA (LIFE), a MedTech company developing next-generation continuous glucose monitoring (CGM) technology, announces that new patent applications have been filed in Europe and the United States related to surface acoustic wave (SAW) sensing for osmotic glucose measurement.

SAW sensors are tiny chips that detect extremely small surface vibrations and are already widely used in other industries. When combined with Lifecare’s proprietary osmotic principle – where glucose levels are reflected as pressure changes – SAW sensors provide an additional way to measure these changes in very small devices. 

This technology strengthens Lifecare’s roadmap towards further miniaturisation of implantable sensors. The company’s first product generation is based on proven, commercially available piezoresistive pressure sensors, ensuring size, reliability, and manufacturability for today’s needs. 

Alongside Lifecare’s licensed Nano Tunneling Resistor (NTR) technology, SAW represents an alternative option for future miniaturisation – with the potential to improve sensitivity while supporting standardised production methods for faster development. 

The patent applications have been filed by Lifecare’s academic partner Johann Wolfgang Goethe University Frankfurt, under a framework that grants Lifecare defined R&D rights and an option to secure commercial rights. The European application (EP 4 619 744) is scheduled for publication in the European Patent Bulletin on 24 September 2025. 

About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Attachments
Lifecare strengthens miniaturisation roadmap with new patent applications

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.